Expansion of Recurring Sales through Related Consumables and Maintenance Services
First written in FY2016. 31 of 41 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-08-05.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Sales of consumables and other products for the fiscal year were ¥5,816.626 million, up 3.0% year on year. Sales remained solid, with domestic sales of ¥5,061.389 million, up 3.0%, and overseas sales of ¥755.237 million, up 2.9%.」
Full-year sales of related consumables and other products increased 3.0% year on year, confirming the expansion of recurring sales in both domestic and overseas markets. - FY2026-H1AdvancedAnnual report
「Sales of consumables and other products for the six months ended 30 September were ¥2,714.655 million, up 1.7% year on year. Domestic demand remained stable, and domestic sales were ¥2,350.360 million, up 2.8%. Overseas sales were ¥364.294 million, down 4.6%, as sales of consumables sold alongside laboratory analyzers declined in line with lower analyzer sales.」
Sales of consumables and other products increased 1.7% year on year, including a 2.8% increase in the domestic market. Overseas sales declined 4.6% alongside lower laboratory analyzer sales, but recurring sales continued to expand overall. - FY2025AdvancedAnnual report
「Sales of consumables and other products for the fiscal year were ¥5,647.659 million, up 4.9% year on year. Stable demand continued in both domestic and overseas markets. Domestic sales were ¥4,913.393 million, up 2.8%, while overseas sales were ¥734.266 million, up 21.4%, in line with the increase in equipment sales.」
Full-year sales of consumables and other products increased 4.9% year on year, with higher sales in both domestic and overseas markets. Overseas consumables sales expanded alongside the increase in equipment sales. - FY2025-H1AdvancedAnnual report
「Sales of consumables and other products for the six months ended 30 September were ¥2,668.524 million, up 3.3% year on year. Stable demand continued in both domestic and overseas markets. Domestic sales were ¥2,286.706 million, up 2.3%, while overseas sales were ¥381.817 million, up 9.3%, in line with the increase in equipment sales.」
First-half sales of consumables and other products increased 3.3% year on year, with higher sales in both domestic and overseas markets. The increase in overseas consumables sales accompanying higher equipment sales was also noted, and recurring sales continue to expand. - FY2024AdvancedAnnual report
「Sales of consumables and other products for the fiscal year were ¥5,385.610 million, up 3.5% year on year. Stable demand continued in both domestic and overseas markets. Domestic sales were ¥4,780.810 million, up 3.3%, while overseas sales were ¥604.800 million, up 5.4%.」
Sales of consumables and other products increased 3.5% year on year, with higher sales in both domestic and overseas markets. Recurring sales from related consumables, maintenance and other services have recovered and expanded since the blood collection tube supply business was discontinued. - FY2024-Q3AdvancedAnnual report
「Sales of consumables and other products for the nine months ended 31 December were ¥3,904.372 million, up 2.9% year on year. Solid demand continued in both domestic and overseas markets. Domestic sales were ¥3,436.365 million, up 2.2%, while overseas sales were ¥468.006 million, up 8.6%.」
Sales of consumables and other products increased 2.9% year on year, with higher sales in both domestic and overseas markets. Recurring sales have recovered and expanded since the blood collection tube supply business was discontinued in the previous fiscal year. - FY2024-Q2AdvancedAnnual report
「Sales of consumables and other products for the six months ended 30 September were ¥2,583.978 million, up 3.7% year on year. Solid demand continued in both domestic and overseas markets. Domestic sales were ¥2,234.640 million, up 1.2%, while overseas sales were ¥349.337 million, up 22.3%.」
Sales of consumables and other products increased 3.7% year on year, with higher sales in both domestic and overseas markets. Overseas sales were particularly strong, increasing 22.3%, and recurring sales continued to expand. - FY2024-Q1AdvancedAnnual report
「Against this operating backdrop, we further strengthened R&D activities related to our core blood collection tube preparation equipment and associated systems, worked to enhance the solutions we can provide, expanded sales of compact, high-performance new specimen testing equipment, and continued efforts to ensure a stable supply of consumables and other products.」
The company continued efforts to ensure a stable supply of consumables and other products, and sales were ¥1,232.380 million, up 2.2% year on year. Despite the impact of the blood collection tube supply business discontinued in the previous fiscal year, sales of consumables and other products increased overall. - FY2023SoftenedAnnual report
「Domestic sales were ¥4,629.279 million, down 3.4% year on year, mainly because the supply business for blood collection tubes, a consumables product, was discontinued in April 2022.」
Although the company intends to expand recurring sales of related consumables and other products, full-year sales of consumables and other products declined 2.7% year on year due to the discontinuation of the blood collection tube supply business. - FY2023-Q3SoftenedAnnual report
「Sales of consumables and other products for the nine months ended 31 December were ¥3,794.437 million, down 3.8% year on year. Domestic sales were ¥3,363.601 million, down 4.6%, mainly because the supply business for blood collection tubes, a consumables product, was discontinued in April 2022. Overseas sales were ¥430.835 million, up 2.5%, mainly owing to an increase in the number of operating analyzers.」
The discontinuation of the blood collection tube supply business caused domestic sales of consumables and other products to decline 4.6% year on year, resulting in an overall decline of 3.8%. Overseas sales increased on factors including a rise in the number of operating analyzers, but initiatives to expand recurring sales have been partly scaled back. - FY2023-Q2SoftenedAnnual report
「Sales of consumables and other products for the six months ended 30 September were ¥2,492.756 million, down 2.3% year on year. Domestic sales were ¥2,207.123 million, down 3.3%, mainly because the supply business for blood collection tubes, a consumables product, was discontinued in April 2022. Overseas sales were ¥285.632 million, up 6.3%, mainly owing to an increase in the number of operating analyzers.」
The discontinuation of the blood collection tube supply business continued to weigh on domestic sales, and sales of consumables and other products declined 2.3% year on year. Initiatives to expand recurring sales have been affected by the partial discontinuation. - FY2023-Q1SoftenedAnnual report
「Sales of consumables and other products for the three months ended 30 June were ¥1,206.148 million, down 3.3% year on year. Domestic sales were ¥1,056.019 million, down 4.2%, mainly because the supply business for blood collection tubes, a consumables product, was discontinued in April 2022.」
Sales of consumables and other products declined 3.3% year on year. The discontinuation of the blood collection tube supply business in April 2022 was cited as a factor in the domestic decline. Initiatives to expand recurring sales of related consumables have been partly scaled back. - FY2022AdvancedAnnual report
「Sales of consumables and other products for the fiscal year were ¥5,345.655 million, up 7.0% year on year. In the previous fiscal year, the frequency of use of our products for routine testing had declined as the number of visitors fell due to COVID-19. As conditions gradually normalized, domestic sales were ¥4,792.318 million, up 5.4%, while overseas sales were ¥553.337 million, up 23.1%, mainly because sales of consumables increased as the number of operating laboratory analyzers rose.」
Sales of consumables and other products increased 7.0% year on year, with recurring-revenue sales recovering in both domestic and overseas markets. - FY2022-Q3AdvancedAnnual report
「Sales of consumables and other products for the nine months ended 31 December were ¥3,944.260 million, up 7.7% year on year. In the same period of the previous year, the frequency of use of our products for routine in-hospital testing had declined due to COVID-19. As conditions returned to normal, domestic sales were ¥3,524.044 million, up 5.7%, while overseas sales were ¥420.215 million, up 28.2%, owing to a substantial increase in sales of consumables used with laboratory analyzers.」
Sales of consumables and other products increased 7.7% year on year, with higher sales in both domestic and overseas markets. The factors cited were the recovery in the frequency of routine testing in Japan and increased overseas sales of consumables used with laboratory analyzers. - FY2022-Q2AdvancedAnnual report
「Sales of consumables and other products for the six months ended 30 September were ¥2,551.530 million, up 9.7% year on year. In the same period of the previous year, the frequency of use of our products for routine in-hospital testing had declined due to COVID-19. As conditions returned to normal, domestic sales were ¥2,282.705 million, up 8.2%, while overseas sales were ¥268.824 million, up 24.0%, owing to a substantial increase in sales of consumables used with laboratory analyzers.」
Sales of consumables and other products increased 9.7% year on year, with higher sales in both domestic and overseas markets. Factors cited included the frequency of routine in-hospital testing gradually returning to normal and increased sales of consumables used with laboratory analyzers. - FY2022-Q1AdvancedAnnual report
「Sales of consumables and other products for the three months ended 30 June were ¥1,246.722 million, up 15.0% year on year. In the same period of the previous year, the frequency of use of our products for routine in-hospital testing had declined due to COVID-19. As conditions returned to normal, domestic sales were ¥1,102.584 million, up 12.0%, and overseas sales were ¥144.138 million, up 44.3%.」
Sales of consumables and other products increased 15.0% year on year, with higher sales in both domestic and overseas markets. The increase was attributed to the frequency of routine in-hospital testing gradually returning to normal. - FY2021WorsenedAnnual report
「Sales of consumables and other products for the fiscal year were ¥4,996.462 million, down 0.2% year on year.」
Full-year sales of consumables and other products declined 0.2% year on year. Domestic sales declined 2.7%, while overseas sales increased 35.1% as sales of blood gas analyzers increased. - FY2021-Q3WorsenedAnnual report
「Sales of consumables and other products for the nine months ended 31 December were ¥3,661.336 million, down 2.1% year on year. Domestic sales were ¥3,333.681 million, down 5.1%, mainly because the frequency of use of our products for routine in-hospital testing declined as the number of outpatients fell due to COVID-19. Overseas sales were ¥327.654 million, up 44.1%, mainly because orders for consumables used with blood gas analyzers increased.」
Sales of consumables and other products declined 2.1% year on year, including a 5.1% decline in the domestic market due to fewer outpatients and lower testing frequency. Overseas sales increased, but recurring-revenue sales deteriorated overall. - FY2021-Q2WorsenedAnnual report
「Revenue from consumables and other products for the first six months ended ¥2,326.495 million, down 4.9% year on year. Domestic revenue fell 8.2% to ¥2,109.787 million as the number of outpatients declined amid the impact of COVID-19, reducing the frequency with which the company’s products were used for routine testing at medical facilities. Overseas revenue increased 46.7% to ¥216.708 million, mainly because orders for consumables used with blood gas analyzers were concentrated in the period.」
Sales of consumables and other products declined 4.9% year on year, including an 8.2% decline in the domestic market. Overseas sales increased, but recurring-revenue sales deteriorated overall. - FY2021-Q1WorsenedAnnual report
「Revenue from consumables and other products for the first quarter ended ¥1,084.108 million, down 6.1% year on year. Domestic revenue fell 9.8% to ¥984.234 million as the number of outpatients declined amid the impact of COVID-19, reducing the frequency with which the company’s products were used for routine testing at medical facilities. Overseas revenue increased 55.3% to ¥99.873 million, mainly because orders for consumables used with blood gas analyzers were concentrated in the period.」
Revenue from consumables and other products fell 6.1% year on year, including a 9.8% decline in Japan due to the decrease in outpatients and lower testing frequency. Overseas revenue increased, but recurring transaction revenue declined overall. - FY2020AdvancedAnnual report
「Revenue from consumables and other products for the fiscal year was ¥5,006.272 million, up 2.0% from the previous fiscal year. Domestic revenue increased 2.6% to ¥4,673.664 million in line with growth in cumulative unit sales, while overseas revenue fell 5.8% to ¥332.607 million.」
Revenue from consumables and other products increased 2.0% for the full year against the previous fiscal year, confirming the expansion of recurring transactions in Japan against the backdrop of growth in cumulative unit sales. - FY2020-Q3AdvancedAnnual report
「Revenue from consumables and other products for the first nine months ended ¥3,738.646 million, up 2.7% year on year. Domestic revenue was ¥3,511.226 million, up 4.4%, and overseas revenue was ¥227.420 million, down 18.3%.」
Revenue from consumables and other products increased 2.7% year on year, including a 4.4% increase in Japan. Although overseas revenue fell 18.3%, revenue from recurring transactions through related consumables increased overall. - FY2020-Q2AdvancedAnnual report
「Revenue from consumables and other products for the first six months ended ¥2,445.648 million, up 5.0% year on year. Domestic revenue was ¥2,297.951 million, up 6.4%, and overseas revenue was ¥147.697 million, down 12.8%.」
Revenue from consumables and other products increased 5.0% year on year, including a 6.4% increase in Japan. Although overseas revenue fell 12.8%, recurring transaction revenue increased overall. - FY2020-Q1AdvancedAnnual report
「Revenue from consumables and other products for the first quarter ended ¥1,154.887 million, up 3.1% year on year. Domestic revenue was ¥1,090.593 million, up 4.8%, and overseas revenue was ¥64.294 million, down 18.9%.」
Revenue from consumables and other products increased 3.1% year on year, including a 4.8% increase in Japan. Although overseas revenue fell 18.9%, revenue from recurring transactions increased overall. - FY2019AdvancedAnnual report
「Revenue from consumables and other products for the fiscal year was ¥4,908.727 million, up 6.4% from the previous fiscal year. In line with the increase in cumulative unit sales, domestic revenue was ¥4,555.745 million, up 6.1%, and overseas revenue was ¥352.981 million, up 10.6%.」
Revenue from consumables and other products increased 6.4% against the backdrop of growth in cumulative unit sales, confirming expansion of recurring transaction revenue in both Japan and overseas. - FY2019-Q3AdvancedAnnual report
「Revenue from consumables and other products for the first nine months ended ¥3,640.757 million, up 8.3% year on year. In line with the increase in cumulative unit sales, revenue increased in both Japan, to ¥3,362.325 million, up 7.5%, and overseas, to ¥278.432 million, up 18.9%.」
Revenue from consumables and other products increased 8.3% year on year against the backdrop of growth in cumulative unit sales, with revenue increasing in both Japan and overseas. Expansion of recurring transactions through related consumables is progressing. - FY2019-Q2AdvancedAnnual report
「Revenue from consumables and other products for the first six months ended ¥2,328.297 million, up 8.0% year on year. Domestic revenue was ¥2,158.830 million, up 7.6%, and overseas revenue was ¥169.467 million, up 13.0%.」
Revenue from consumables and other products increased 8.0% year on year in both Japan and overseas. Expansion of recurring transactions through related consumables has maintained the growth trend seen through the previous quarter. - FY2019-Q1AdvancedAnnual report
「Revenue from consumables and other products for the first quarter ended ¥1,119.707 million, up 4.9% year on year. Domestic revenue was ¥1,040.468 million, up 6.0%, and overseas revenue was ¥79.239 million, down 7.5%.」
Revenue from consumables and other products increased 4.9% year on year, including a 6.0% increase in Japan. Although overseas revenue fell 7.5%, recurring transaction revenue expanded overall. - FY2018AdvancedAnnual report
「Revenue from consumables and other products for the fiscal year was ¥4,613.367 million, up 7.3% from the previous fiscal year. In Japan, revenue increased steadily in line with cumulative unit sales to ¥4,294.199 million, up 8.4%.」
Revenue from consumables and other products increased 7.3% from the previous fiscal year against the backdrop of growth in cumulative unit sales, and increased 8.4% in Japan. Full-year results confirm progress in expanding recurring transactions. - FY2018-Q3AdvancedAnnual report
「Revenue from consumables and other products for the first nine months ended ¥3,362.380 million, up 7.2% year on year. In Japan, revenue increased in line with cumulative unit sales to ¥3,128.118 million, up 8.1%, while overseas revenue fell 3.6% to ¥234.262 million due to differences in order timing and other factors.」
Revenue from consumables and other products increased 7.2% year on year overall and 8.1% in Japan. Although overseas revenue declined due to differences in order timing and other factors, recurring transaction revenue continued to expand overall. - FY2018-Q2AdvancedAnnual report
「Revenue from consumables and other products for the first six months ended ¥2,155.470 million, up 5.4% year on year. Domestic revenue increased 7.7% to ¥2,005.543 million as sales grew in line with cumulative unit sales. Overseas revenue fell 17.9% to ¥149.927 million because the timing of a large reagent order was delayed.」
Revenue from consumables and other products increased 5.4% year on year overall and 7.7% in Japan. Overseas revenue declined because a large reagent order was delayed, but expansion of recurring transactions progressed overall. - FY2018-Q1AdvancedAnnual report
「Revenue from consumables and other products for the first quarter ended ¥1,067.433 million, up 7.8% year on year. Sales increased in both Japan and overseas in line with growth in cumulative unit sales. Domestic revenue was ¥981.785 million, up 6.3%, and overseas revenue was ¥85.647 million, up 29.2%.」
Revenue from consumables and other products increased 7.8% year on year against the backdrop of growth in cumulative unit sales. Recurring transaction revenue is expanding in both Japan and overseas. - FY2017AdvancedAnnual report
「Revenue from consumables and other products for the fiscal year was ¥4,299.734 million, up 0.2% from the previous fiscal year. Domestic revenue declined slightly to ¥3,960.681 million, down 0.8%, while overseas revenue was ¥339.052 million, up 12.9%, in line with the increase in cumulative unit sales.」
Revenue from consumables and other products increased 0.2% overall from the previous fiscal year and 12.9% in overseas markets. Full-year results confirm progress in expanding recurring transactions. - FY2017-Q3AdvancedAnnual report
「Revenue from consumables and other products for the first nine months ended ¥3,135.886 million, up 1.7% year on year. Sales of consumables remained firm as the cumulative number of units sold increased. Revenue in Japan was ¥2,892.993 million, up 1.2%, and overseas revenue was ¥242.893 million, up 8.4%.」
Revenue from consumables and other products increased 1.7% year on year against the backdrop of growth in cumulative unit sales. Sales progress in recurring transactions was evident in both Japan and overseas. - FY2017-Q2WorsenedAnnual report
「Revenue from consumables and other products for the first six months ended ¥2,044.975 million, down 2.6% year on year.」
While the company aims to expand consumables revenue in line with growth in cumulative unit sales, first-half revenue from consumables and other products fell 2.6% year on year. - FY2017-Q1AdvancedAnnual report
「Revenue from consumables and other products for the first quarter ended ¥989.858 million, up 1.6% year on year. Sales of consumables remained firm as the cumulative number of units sold increased.」
Revenue from related consumables and other products increased 1.6% year on year against the backdrop of growth in cumulative unit sales. This was described as concrete sales progress in expanding recurring transactions. - FY2016First statedAnnual report
「In light of the business environment surrounding our core blood collection tube preparation equipment business, we seek to expand ongoing transactions with existing customers through recurring revenue from related consumables and maintenance services, which can be expected to generate sales in line with growth in the cumulative number of units installed.」
The company’s policy is to expand recurring revenue from proprietary consumables and maintenance services based on the installed equipment base.